Pharma Exclusives Pressreleases
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
Wednesday, August 13, 2025AbbVietoday announced a million investment in its North Chicago Illinois manufacturing plant to expand domestic active pharmaceutical ingredient API production in the US This expansion is part of AbbVies previously announced commitment to invest mor...
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Thursday, August 07, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative nextgeneration treatment options today announced that its Clinical Trial Application CTA
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Friday, August 01, 2025GRI Bio Inca biotechnology company advancing an innovative pipeline of Natural Killer T NKT cell modulators for the treatment of inflammatory fibrotic and autoimmune diseases today reported interim week biomarker results
Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States
Friday, August 01, 2025Ahead of the publication of its business results for the second quarter of on Wednesday August Bayer AG is providing an update on key financial figures Due to a betterthanexpected business performance
Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Wednesday, July 30, 2025Eisai Co Ltd and Biogen Incannounced today that the latest findings demonstrating the benefits of continuous treatment with lecanemabirmb US brand name LEQEMBI an antiamyloid beta A protofibril
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Monday, July 28, 2025Moderna Inctoday announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion recommending marketing authorization for an updated formulation
Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
Monday, July 28, 2025AstraZenecas supplemental Biologics License Application sBLA for Imfinzi durvalumab has been accepted and granted Priority Review in the US for the treatment of patients with resectable earlystage and locally advanced
START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials
Friday, July 25, 2025The START Center for Cancer Research START the leading global communitybased earlyphase oncology research network today announced a strategic partnership with Advarra the premier provider
Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential
Friday, July 25, 2025AstraZenecas Trixeo Aerosphere budesonideglycopyrroniumformoterol fumarate or BGF already licensed for the treatment of chronic obstructive pulmonary disease COPD in adults has received a positive opinion
Coriolis Pharma Opens New Laboratory at Spark Life Science Campus in Morrisville, North Carolina
Wednesday, July 23, 2025Coriolis Pharma a globally operating Contract Research and Development Organization CRDO and a leader in formulation research and development for biopharmaceuticals today announced its intention to invest million
